Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041

Reuters2026/07/30 12:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Savara secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending protection through March 2041.
The Europe grant is European patent No. 4121000; the Australia grant is patent No. 62/990,810.
The announcement strengthens intellectual property coverage for MOLBREEVI outside the US as Savara advances related US filings.
Savara cited a separate joint European patent with PARI for a MOLBREEVI drug-device combination, running through March 2043.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300805BIZWIRE_USPR_____20260730_BW546415) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041

You may also like

Crypto prices